title: The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
abstract: The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) has revolutionized the outcome, but the prognosis of the disease is still based on prognostic systems that were developed in the era of conventional chemotherapy and interferon (IFN)-alfa. A new prognostic score including only two variables, spleen size and basophils, was developed for the prediction of complete cytogenetic response (CCyR) and progression-free survival (PFS). The score was based on a large series of patients who were enrolled in prospective multicenter studies of first-line imatinib treatment. The prognostic value of the EUTOS (European Treatment and Outcome Study for CML) score has now been tested in an independent, multicenter, multinational series of 1288 patients who were treated first-line with imatinib outside prospective studies. It was found that also in these patients, the EUTOS prognostic score was predictive for CCyR, PFS and overall survival (OS). In addition, the prognostic value of the score was reported to be significant in seven of the eight other independent studies of almost 2000 patients that were performed in Europe, the Americas and Asia. The EUTOS risk score is a valid tool for the prediction of the therapeutic effects of TKI, particularly imatinib.
authors.affiliation: Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, München, Germany.
authors.forename: V S
authors.initials: VS
authors.lastname: Hoffmann
authors.forename: M
authors.initials: M
authors.lastname: Baccarani
authors.forename: D
authors.initials: D
authors.lastname: Lindoerfer
authors.forename: F
authors.initials: F
authors.lastname: Castagnetti
authors.forename: A
authors.initials: A
authors.lastname: Turkina
authors.forename: A
authors.initials: A
authors.lastname: Zaritsky
authors.forename: A
authors.initials: A
authors.lastname: Hellmann
authors.forename: W
authors.initials: W
authors.lastname: Prejzner
authors.forename: J-L
authors.initials: JL
authors.lastname: Steegmann
authors.forename: J
authors.initials: J
authors.lastname: Mayer
authors.forename: K
authors.initials: K
authors.lastname: Indrak
authors.forename: A
authors.initials: A
authors.lastname: Colita
authors.forename: G
authors.initials: G
authors.lastname: Rosti
authors.forename: M
authors.initials: M
authors.lastname: Pfirrmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D015996:Survival Rate; D054928:Validation Studies as Topic; D055815:Young Adult
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases